Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine

D A Harbour, D A Gunn-Moore, T J Gruffydd-Jones, S M A Caney, J Bradshaw, O Jarrett, A Wiseman

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The duration of immunity provided by a feline leukemia virus (FeLV) vaccine, Leukocell 2, was determined. Kittens were vaccinated when 9 and 12 weeks of age and were challenged 12 months later with FeLV-A/Glasgow-1. An oronasal challenge protocol without corticosteroid enhancement was developed in order to induce a persistent viraemia in a high proportion of adult cats. Fourteen of 18 (80%) of the vaccinated cats challenged in this way remained non-viraemic while 9/15 (60%) of age-matched controls became persistently infected, a preventable fraction of 63%. This difference was statistically significant (P=0.038). For comparison, 10 of 12 (83%) 15-17-week-old kittens challenged in the same way became persistently infected, confirming the relative resistance of adult animals to FeLV. Tests for virus neutralising and anti-feline oncornavirus-associated cell membrane antigen (FOCMA) antibodies suggested that the former were more important than the latter in protection. Thus, Leukocell 2 protected a significant proportion of cats from FeLV challenge 1 year after primary vaccination as kittens.
Original languageEnglish
Pages (from-to)2866-72
Number of pages7
JournalVaccine
Volume20
Issue number23-24
DOIs
Publication statusPublished - 26 Jul 2002

Keywords / Materials (for Non-textual outputs)

  • Animals
  • Tumor Virus Infections
  • Antigens, Viral
  • Gene Products, gag
  • Leukemia Virus, Feline
  • Virulence
  • Antibodies, Viral
  • Cat Diseases
  • Viral Vaccines
  • Retroviridae Proteins, Oncogenic
  • Cats
  • Neutralization Tests
  • Nose
  • Viremia
  • Mouth
  • Time Factors
  • Retroviridae Infections
  • Female
  • Male
  • Retroviridae Proteins

Fingerprint

Dive into the research topics of 'Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine'. Together they form a unique fingerprint.

Cite this